There is a clear unmet need for innovative treatments that can suppress ongoing inflammatory disease activity in treatment refractory relapsing-remitting MS (RRMS) patients. The grant of the Belgian Charcot Foundation enables us to start developing CD19 CAR T cells for the use in MS and related autoimmune diseases that are driven by pathogenic B cells. While the current project is focused on laboratory research, we are committed to paving the road towards a first-in-man clinical trial in the future.